Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 10, 2023 09:59 ET | Source: Oryzon Genomics, S.A.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2023

Positive results from interim analysis of vafidemstat's PORTICO Phase IIb trial in Borderline Personality DisorderRecruiting patients in FRIDA trial with iadademstat in combination with gilteritinib...
May 09, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Give Updates on Corporate Progress in May-June

BioEquity Europe 2023Foro Medcap BME 2023 VI Ibero-American Congress CEAPI 2023BIO International Conference 2023Jefferies Healthcare Conference 2023MidCap Paris 2023 MADRID and BOSTON, May 09, 2023 ...
April 03, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder

Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the trial MADRID, Spain and BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- Oryzon...
March 15, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed/Refractory FLT3-mutant Acute Myeloid Leukemia Patients

In combination with gilteritinibPrimary objectives: to assess safety, tolerability and RP2DSecondary objectives: to assess efficacy MADRID, Spain and BOSTON, March 15, 2023 (GLOBE NEWSWIRE) --...
March 13, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders

A highly selective HDAC-6 inhibitorRescues motor-neuronal deficiencies in a Charcot-Marie-Tooth modelTo start IND enabling studies MADRID, Spain and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) --...
February 22, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology

MADRID, Spain and BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
February 17, 2023 10:08 ET | Source: Oryzon Genomics, S.A.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022

Strong clinical progress in both oncology and CNS Cash, cash equivalents and marketable securities totaled $22.7 million as of December 31, 2022 MADRID, Spain and BOSTON, Feb. 17, 2023 ...
February 06, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Give Updates on Corporate Progress in February-March

BIO CEO & Investor Conference 2023 IASLC 2023 Targeted Therapies of Lung Cancer Meeting 16th Annual European Life Sciences CEO ForumCancer Epigenetics Institute Symposium: From Genes to Chromatin...
January 18, 2023 08:12 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas

Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECsPart of a broad collaboration with The Cancer Epigenetics...
January 05, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Give Updates on Corporate Progress in January

6th Sachs Annual Neuroscience Innovation Forum12th Annual LifeSci Advisors Corporate Access Event41st Annual J.P. Morgan Healthcare ConferenceInvest Securities Biomed Forum 2023 MADRID, Spain and...